Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine vs Conventional Care in High-Risk MDS
NCT00071799Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2003
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of azacitidine in myelodysplastic syndrome (MDS) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Median Time to Death From Any Cause at 42 months. Started Nov 2003; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00071799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071799.